FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 521 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French Clinical Activity of Elraglusib with Gemcitabine Plus Nab-paclitaxel in First-Line Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma MOST POPULAR What to Know About Navigating Cancer Care With a Disability: An... May 4, 2023 Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity... September 10, 2024 ESMO Welcomes EU Proposals for MFF & FP10 and Calls for... July 21, 2025 Courageous children receive Star Awards in virtual celebration December 17, 2021 Load more HOT NEWS Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... New on NCI’s Websites for June 2022
